Non-opioid niche Target opportunity around non-opioid back pain therapies, highlighting SP-102 as a first-in-class non-opioid injectable corticosteroid gel for chronic sciatica, appealing to clinicians seeking non-addictive alternatives.

FDA-ready pipeline Position SP-102 for accelerated conversations with payer and regulatory teams due to its preservative-free, particulate-free formulation, which may translate to improved safety profiles and marketability in the US spine pain space.

Partnership potential Leverage plans for US commercialization and international partnerships to pursue co-development, regional distribution, or licensing deals with mid to large pharma and specialty distributors in pain management.

Back pain market dynamics Capitalize on the high and rising opioid usage in North America by framing SP-102 as a strategic substitution option for patients with moderate to severe radicular pain, supporting formulary positioning and clinical adoption studies.

Early-stage funding context Align business development with Semnur’s substantial funding runway ($106M) to seek strategic alliances, joint ventures, or milestone-driven partnerships that accelerate late-stage development and commercialization.